ALNY

Alnylam Pharmaceuticals
ALNY

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$40.16B
EV
$40.25B
Shares Outstanding
133.39M
Beta
0.21

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$320.88
P/E 2025E
-
P/Revenue 2025E
13.85x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Alnylam Pharmaceuticals, Inc.

gainify
ALNY

Alnylam Pharmaceuticals, Inc.

ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of...

Sector

Healthcare

Industry

Biotechnology

CEO

Greenstreet, Yvonne

Employees

2,230

IPO Date

2004-06-01

Headquarters

675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts, 02142, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.